The Effect of ANGIPARS™ on Wound Healing in Patients with Diabetes: A Systematic Review

Abstract

About 15% of patients with diabetes develop a Diabetic foot ulcer (DFU). It is an open sore or wound commonly located on the bottom of the foot.ANGIPARS™ is an Iranian-produced herbal remedy based on the extract of <em>Melilotus officinalis</em>. The aim of this study was to make a systematic review focused on determination of the effect of ANGIPARS™ on wound healing in patients with diabetes. The study was conducted in accordance with the PRISMA guidelines. Articles included in the review cover the period from the discovery of ANGIPARS™ to August 18, 2018. The data were analyzed using a descriptive method of Excel 2007 Software.Five articles with total number of 171 patients were included in the systematic review (SR) phase. In three articles, the methods were based on mm²units and in the two others on cm²units. Patients' follow-up varied from 4 weeks to 6 months after the intervention. In all patients, ANGIPARS™ responds well to the DFU disease. Due to the positive effect of the herbal drug, it is recommended to administer it for wound healing in patients with diabetes.